Board to approve September quarter and half-year results

Revenue declinedEBITDA margin compressionResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.4%Reaction day

₹42.80

prior close

₹44.00

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.7%-0.3% vs market

Pharmaceuticals peers, median of 171sector+0.4%-0.0% vs sector

On the reaction day the stock moved 0.3 pts less than Nifty Microcap 250 and in line with its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.1

10m

-2.3

15m

-2.3

30m

-4.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.4+0.7-0.3+0.4-0.0

Next day

-4.1-1.9-2.2-0.6-3.5

-2.8-0.4-2.4-0.4-2.4

+5.1-0.2+5.3-0.1+5.3

+5.1+2.0+3.1+0.7+4.5

+8.7+3.1+5.5+1.8+6.9

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 171Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

The Board will meet on November 5, 2026 to approve the company's unaudited standalone results for the quarter and half year ended September 30, 2026. The figures will receive a limited review from the statutory auditor. The trading window has been closed since October 1 and will remain closed until 48 hours after results are declared, currently stated as November 7.

Likely market impact

This is a routine meeting notice with no financial figures or outlook. Investors must wait for the November 5 results for a fundamental view.

By the numbersStandalone · Q2 FY27 vs Q2 FY26

	Q2 FY27	Q2 FY26	Change
Revenue	₹12.78 Cr	₹12.93 Cr	−1.2%
Operating profit	₹1.51 Cr	₹1.73 Cr	−12.4%
Profit after tax	₹1.32 Cr	₹1.40 Cr	−6.0%
EBITDA margin	13.0%	14.6%	−1.6 pp

From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.